Interpace Biosciences has appointed Fortunato Ron Rocca as a class II director. Rocca will serve on the firm's board as a non-employee director. Concurrently with the appointment, Felice Schnoll-Sussman has resigned from Interpace Bio's board. Rocca currently serves as president and CEO of Exagen.
Interpace Bio also said that CFO and Treasurer James Early is retiring from the firm. Early will be replaced by Fred Knechtel, who previously served as CFO at Genewiz.
Interpace Bio has also appointed Jeff Salzman as VP of managed care and payor relations. Prior to Interpace Bio, Salzman held roles at Quest Diagnostics, Monogram Biosciences, Vermillion, and most recently at CareDx.